CFTR and cystic fibrosis: ETI therapy leads to substantial clinical benefits and improvement in CFTR function to 40 to 50% of normal CFTR activity measured by nasal potential difference (NPD), intestinal current measurement (ICM), lung clearance index (LCI) and lung morphology in real world observational trials in patients with CF and at least one F508del mutation [10,11].